IDEXX Laboratories, Inc. $IDXX Shares Acquired by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 54.4% during the first quarter, HoldingsChannel reports. The institutional investor owned 9,213 shares of the company’s stock after acquiring an additional 3,247 shares during the period. Banque Cantonale Vaudoise’s holdings in IDEXX Laboratories were worth $5,177,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Empowered Funds LLC lifted its stake in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $265,000. Jump Financial LLC raised its holdings in shares of IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after acquiring an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC purchased a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $164,000. Finally, Sei Investments Co. increased its position in shares of IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. UBS Group lowered their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Up 1.5%

IDEXX Laboratories stock opened at $549.16 on Thursday. The company has a market capitalization of $43.32 billion, a PE ratio of 40.44, a price-to-earnings-growth ratio of 2.96 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The firm has a 50 day moving average price of $559.95 and a 200 day moving average price of $616.34.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the firm earned $2.91 earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.